share_log

Shenzhen Noposion Crop Science's (SZSE:002215) Earnings Growth Rate Lags the 12% CAGR Delivered to Shareholders

Shenzhen Noposion Crop Science's (SZSE:002215) Earnings Growth Rate Lags the 12% CAGR Delivered to Shareholders

深圳諾普信農業科技股份有限公司(SZSE:002215)的盈利增長率低於向股東提供的12%的年複合增長率(CAGR)
Simply Wall St ·  07/18 20:07

It might be of some concern to shareholders to see the Shenzhen Noposion Crop Science Co., Ltd. (SZSE:002215) share price down 11% in the last month. But that doesn't change the fact that the returns over the last three years have been pleasing. After all, the share price is up a market-beating 32% in that time.

上個月深圳諾普信股份有限公司(SZSE:002215)的股價下跌了11%,可能引起股東們的一些關注。但事實並未改變,過去三年的回報令人滿意。畢竟,在那段時間裏,股價上漲了32%,超過市場表現。

In light of the stock dropping 7.3% in the past week, we want to investigate the longer term story, and see if fundamentals have been the driver of the company's positive three-year return.

考慮到這支股票在過去一週內下跌了7.3%,我們希望調查長期的情況,看看基本面是否推動了公司的三年回報。

While the efficient markets hypothesis continues to be taught by some, it has been proven that markets are over-reactive dynamic systems, and investors are not always rational. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

雖然一些人仍然在教授高效市場假說,但已經證明市場是過度反應的動態系統,投資者不總是理性的。一種有缺陷但合理的評估公司情緒變化的方法是比較每股收益 (EPS) 與股價。

Shenzhen Noposion Crop Science was able to grow its EPS at 32% per year over three years, sending the share price higher. The average annual share price increase of 10% is actually lower than the EPS growth. Therefore, it seems the market has moderated its expectations for growth, somewhat.

深圳市諾普信農業科技股份有限公司每股收益在過去三年中以32%的年增長率增長,推高了股價。10%的年平均股價增長實際上低於每股收益的增長。因此,市場似乎已經適度降低了對增長的預期。

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

下面可以看到每股收益隨時間的變化情況(通過點擊圖像來查看確切數值)。

big
SZSE:002215 Earnings Per Share Growth July 19th 2024
深圳證券交易所:002215股票每股收益增長於2024年7月19日

It is of course excellent to see how Shenzhen Noposion Crop Science has grown profits over the years, but the future is more important for shareholders. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.

諾普信在過去的幾年裏增長了利潤,當然這很棒,但對於股東來說,未來更重要。查看我們的免費報告,了解其財務狀況如何隨着時間的推移而變化,這是非常值得的。

What About Dividends?

那麼分紅怎麼樣呢?

When looking at investment returns, it is important to consider the difference between total shareholder return (TSR) and share price return. The TSR incorporates the value of any spin-offs or discounted capital raisings, along with any dividends, based on the assumption that the dividends are reinvested. So for companies that pay a generous dividend, the TSR is often a lot higher than the share price return. As it happens, Shenzhen Noposion Crop Science's TSR for the last 3 years was 42%, which exceeds the share price return mentioned earlier. The dividends paid by the company have thusly boosted the total shareholder return.

在考慮投資回報時,重要的是要考慮總股東回報(TSR)和股價回報之間的差異。TSR包括任何拆分或折價融資的價值,以及任何股息,基於股息再投資的假設。因此,對於支付慷慨的股息的公司,TSR通常比股價回報高得多。恰巧,諾普信過去3年的TSR爲42%,超過了前面提到的股價回報。該公司支付的股息因此提高了總股東回報。

A Different Perspective

不同的觀點

While it's certainly disappointing to see that Shenzhen Noposion Crop Science shares lost 1.0% throughout the year, that wasn't as bad as the market loss of 17%. Of course, the long term returns are far more important and the good news is that over five years, the stock has returned 4% for each year. In the best case scenario the last year is just a temporary blip on the journey to a brighter future. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. To that end, you should be aware of the 2 warning signs we've spotted with Shenzhen Noposion Crop Science .

雖然看到深圳諾普信的股票在整個年份中下跌了1.0%,但這並不像市場虧損17%那樣糟糕。當然,長期回報更爲重要,好消息是,在過去的五年中,該股每年回報率爲4%。在最理想的情況下,去年只是通往更光明未來的旅程中的臨時波動。雖然考慮市場條件對股價影響的差異非常值得,但有其他因素更爲重要。爲此,您應該注意到我們已經發現了深圳諾普信的2個警示標誌。

If you are like me, then you will not want to miss this free list of undervalued small caps that insiders are buying.

如果您像我一樣,就不會希望錯過這份免費的內部人士正在購買的低估小市值股票列表。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論